The bottleneck in AI-driven cancer care is infrastructure, not just algorithms. Legacy medical systems are built for megabytes of data, but full genomic sequencing generates hundreds of gigabytes per patient. Progress requires a new data science platform capable of handling and analyzing this massive scale.

Advanced AI models are ineffective in clinical settings without a robust data layer. Ambience had to solve fundamental problems like pulling messy context from inconsistent EHRs and preserving 'decision traces,' which are often destroyed by existing systems with mutable data structures.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

The development of powerful foundation models to optimize bioprocessing is hampered less by technical challenges and more by the industry's reluctance to share data. The critical challenge is overcoming the cultural and legal hurdles within companies to create the large, diverse datasets necessary for transformative AI.

Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.

The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.

For industries like healthcare and finance, the primary obstacle to deploying AI isn't the technology's capability but the state of their own data. Many organizations lack the proper data formatting and security infrastructure, making it impossible to "unleash" AI on their most valuable information.